PMID: 9450816Feb 5, 1998Paper

Allogeneic bone marrow transplantation for systemic AL amyloidosis

British Journal of Haematology
Julian D GillmoreP N Hawkins

Abstract

Low-intensity chemotherapy is ineffective in most patients with AL amyloidosis, probably because clinical benefit requires regression of the amyloid deposits, and this occurs only very gradually after the underlying plasma cell dyscrasia has been suppressed. We report the first successful allogeneic bone marrow transplant (allo-BMT) for AL amyloidosis, which after 3 years was associated with complete clinical recovery. This supports the idea that there may be a brief window of opportunity in patients with AL amyloidosis during which dose-intensive chemotherapy is feasible and most likely to produce clinical benefit.

References

Apr 16, 1992·The New England Journal of Medicine·R Koffman
Jan 1, 1992·Leukemia Research·D TopolskyI Brodsky
Aug 23, 1990·The New England Journal of Medicine·P N HawkinsM B Pepys
Aug 1, 1995·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S Y TanP N Hawkins
Apr 1, 1995·Annals of Internal Medicine·M van BurenH M Lokhorst

❮ Previous
Next ❯

Citations

Mar 3, 2007·Clinical Rheumatology·J CalatayudF Hernando Trancho
Oct 30, 2012·Bone Marrow Transplantation·M RosenzweigH Landau
Aug 26, 2006·Nature Clinical Practice. Nephrology·Julian D Gillmore, Philip N Hawkins
Mar 27, 2001·Respirology : Official Journal of the Asian Pacific Society of Respirology·M E HowardC F McDonald
Jan 12, 2002·Kidney International·Morie A GertzAngela Dispenzieri
Jun 7, 2002·The New England Journal of Medicine·Helen J LachmannPhilip N Hawkins
Apr 23, 2003·Cardiology in Review·Sameer K MehtaJames A De Lemos
Jun 3, 2000·Transplant International : Official Journal of the European Society for Organ Transplantation·G NowakB G Ericzon
Apr 22, 1999·Thorax·J D Gillmore, P N Hawkins
Nov 22, 2011·Journal of Hematology & Oncology·Michael Rosenzweig, Heather Landau
Feb 6, 2014·Haematologica·Shameem MahmoodAshutosh Wechalekar
Jun 8, 2004·British Journal of Haematology·UNKNOWN Guidelines Working Group of UK Myeloma Forum, UNKNOWN British Commitee for Standards in Haematology, British Society for Haematology
Dec 29, 2007·British Journal of Haematology·Ashutosh D WechalekarJulian D Gillmore
Apr 25, 2007·Hematology·Peter JacobsErna Mansvelt
Oct 11, 2014·British Journal of Haematology·Ashutosh D WechalekarUNKNOWN BCSH Committee
May 29, 2000·QJM : Monthly Journal of the Association of Physicians·J D GillmoreP N Hawkins
Dec 2, 2000·Bone Marrow Transplantation·M A GertzM R Litzow
Jan 20, 2005·Circulation·Raymond Y Kwong, Rodney H Falk
Mar 22, 2001·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·M B Pepys
Mar 22, 2006·American Journal of Hematology·Tomoyuki ImamuraJun-ichi Kadota
Dec 11, 1999·Current Opinion in Neurology·Z Simmons

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.